drugset
drugset / Trial / NCT01229553

Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients

NCT01229553 ↗

Withdrawn State University of New York - Upstate Medical University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to measure efficacy of our new protocol by monitoring the results of our routine respiratory cultures at the end of the new standard treatment, and during routine visits for 1 year from initiation of therapy for Staphylococcus aureus. The secondary objective will include determining the clinical course (pulmonary exacerbations, antibiotic use, hospitalizations, pulmonary function tests) of patients who underwent the protocol.

Timeline

Start
2011-01
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CEPHALEXIN ANHYDROUS Small molecule 100 mg/kg —
Subject Mupirocin Small molecule — Topical
Subject T/S Unknown 20 mg/kg Oral

Indications

cystic fibrosis